A. Menter

Publications476
h-index86
Citations31,215
Highly Influential Citations1,032
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Lebwohl
  • 1,039 Publications • 41,085 Citations
  • A. Gottlieb
  • 745 Publications • 36,334 Citations
  • J. Krueger
  • 606 Publications • 46,868 Citations
  • K. Papp
  • 503 Publications • 29,204 Citations
  • Publications
  • Influence
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
View on PubMed
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
TLDR
Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris and has a good cost-benefit ratio, but the potentially significant costs for, and time required of, the patient must be considered.
View on Wiley
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
View on PubMed
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
TLDR
The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
View on PubMed
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
TLDR
Bdalumab significantly improved plaque psoriasis in this 12-week, phase 2 study and was superior to placebo in all comparisons.
View on PubMed
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
View on Elsevier
Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways
TLDR
The results provide strong support for the association of at least seven genetic loci and psoriasis (each with combined P < 5 × 10−8) and suggest priority targets for study in other auto-immune disorders.
View on Nature
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
View on PubMed
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.
View on PubMed
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
View on PubMed
...
...